Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Allergan Inc., consolidated balance sheet: assets

US$ in thousands

	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Cash and equivalents	4,911,400)	3,046,100)	2,701,800)	2,406,100)	1,991,200)
Short-term investments	55,000)	603,000)	260,600)	179,900)	749,100)
Trade receivables, net	914,500)	883,300)	764,200)	730,600)	647,300)
Inventories	296,000)	285,300)	282,900)	249,700)	229,400)
Prepaid expenses	218,400)	157,100)	149,900)	99,800)	64,700)
Deferred taxes	343,500)	277,900)	249,100)	305,600)	277,700)
Foreign currency derivative assets	75,100)	20,400)	—)	—)	—)
Other	57,300)	37,600)	50,300)	76,600)	34,300)
Other current assets	694,300)	493,000)	449,300)	482,000)	376,700)
Assets of discontinued operations	—)	9,000)	—)	—)	—)
Current assets	6,871,200)	5,319,700)	4,458,800)	4,048,300)	3,993,700)
Deferred executive compensation investments	112,900)	100,700)	81,700)	70,900)	64,900)
Capitalized software	37,000)	36,800)	47,300)	57,800)	75,300)
Prepaid pensions	11,100)	5,600)	5,700)	3,500)	7,500)
Prepaid royalties	—)	—)	—)	4,900)	8,500)
Interest rate swap fair value	—)	—)	—)	48,100)	42,300)
Debt issuance costs	8,600)	10,800)	8,000)	9,500)	10,000)
Equity investments	47,200)	20,800)	9,000)	9,000)	7,700)
Other	55,100)	38,500)	40,400)	43,400)	45,200)
Investments and other assets	271,900)	213,200)	192,100)	247,100)	261,400)
Deferred tax assets	86,900)	128,800)	206,900)	152,600)	217,800)
Property, plant and equipment, net	1,006,300)	923,200)	852,900)	807,000)	800,600)
Goodwill	2,392,900)	2,339,400)	2,239,500)	2,088,400)	2,038,600)
Intangibles, net	1,786,500)	1,650,000)	1,229,100)	1,165,200)	996,000)
Non-current assets	5,544,500)	5,254,600)	4,720,500)	4,460,300)	4,314,400)
Total assets	12,415,700)	10,574,300)	9,179,300)	8,508,600)	8,308,100)

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan Inc. current assets increased from 2012 to 2013 and from 2013 to 2014.
Property, plant and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Allergan Inc. property, plant and equipment, net increased from 2012 to 2013 and from 2013 to 2014.
Non-current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Allergan Inc. non-current assets increased from 2012 to 2013 and from 2013 to 2014.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Allergan Inc. total assets increased from 2012 to 2013 and from 2013 to 2014.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Allergan Inc. cash and equivalents increased from 2012 to 2013 and from 2013 to 2014.
Short-term investments	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	Allergan Inc. short-term investments increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.
Trade receivables, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Allergan Inc. trade receivables, net increased from 2012 to 2013 and from 2013 to 2014.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Allergan Inc. inventories increased from 2012 to 2013 and from 2013 to 2014.

Allergan Inc. (NYSE:AGN.)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items